Mayo Clinic News
-
Standard physicals are, well, pretty standard. During a visit geared more toward detecting disease than preventing it, your doctor makes you cough and checks your numbers. If there’s an abnormality -- your blood pressure has spiked or your liver enzymes are elevated -- it’s your schedule that suffers as you’re shuttled between specialists.
-
Chemotherapy, radiation and the use of radioactive follow-up tests aren’t needed for some cancers, according to two studies that add to a growing debate on ways to lessen side effects and lower patient costs.
-
Across the river from Belinda Elida Barja’s two-room apartment, the lead and zinc smelters of Doe Run Peru spread smoke and dust in the mountain town of La Oroya.
-
Mike Hawker travels 3,200 miles from his home in Anchorage to the Mayo Clinic every six months to get a test for microscopic signs that a rare form of prostate cancer he beat three years ago may have returned.
-
UnitedHealth Group Inc., the largest U.S. provider of medical coverage, will join the Mayo Clinic in a research alliance designed to merge insurance records and medical data to find more efficient ways to deliver care.
-
Financial incentives for losing weight help people shed more pounds than programs that don’t affect dieters’ wallets, a study found.
-
Boston Scientific Corp.’s Watchman device, designed to help prevent strokes in patients with an erratic heartbeat, was safer than previously thought in a second study requested by U.S. regulators, researchers said.
-
A group of 45 doctors, insurers and policy makers frustrated by the current state of health care are set to graduate tomorrow from a first-of-a-kind program at Dartmouth College designed to help them improve patient care.
-
Deaths linked to Alzheimer’s have increased in the last decade while those for stroke, breast cancer and HIV have dropped, said researchers calling for more funding for the memory-robbing disease.
-
Repros Therapeutics Inc., maker of an experimental drug to restore normal testosterone levels to men with hypogonadism, gained the most in more than two years after the drug met study goals.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page